Biomatrix Ramping Up Synvisc Production; Analysts Boost 1999 Estimates
This article was originally published in The Gray Sheet
Executive SummaryA new U.S. manufacturing plant will allow Biomatrix to triple its syringe production capability by the fourth quarter of 1999, the company says.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.